The effect of varying degrees of renal impairment on the single dose pharmacokinetic profile of orally administered lurasidone: a phase I study.
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2009
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Dainippon Sumitomo Pharma
- 30 Mar 2009 Planned number of patients changed from 33 to 24 as reported by ClinicalTrials.gov.
- 24 Feb 2009 New trial record